It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
Zacks Investment Research on MSN8h
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...
News Nation on MSN3h
Study links Wegovy to increased hair loss riskResearchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in ...
Pharmaceutical Technology on MSN8h
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shotNovo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback